The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma
Open accessAbstract
Lung premalignancy and early-stage adenocarcinoma use a mechanism of glucose transport that can be targeted for early diagnosis and treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“But an alternative tracer, methyl-4-deoxy-4-[18F]-fluoro-α-d-glucopyranoside (Me4FDG), is taken up by SGLT and can identify AAH and low-grade adenocarcinomas of the lung (24).”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [24]
In the citing paper
“In atypical adenomatous hyperplasias (AAHs) of the lung, premalignant lesions overexpress sodium-dependent glucose transporter 2 (SGLT2).”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longitudinal data analysis using generalized linear models
LIANG, K.-Y., & ZEGER, S. L. (1986) · Biometrika · doi:10.1093/biomet/73.1.13 · Cited by 18,550
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064
The 2015 World Health Organization Classification of Lung Tumors
Travis, W. D., Brambilla, E. M., Nicholson, A. G., Yatabe, Y., Austin, J. H. M., Beasley, M. B., Chirieac, L. R., Đačić, S., Duhig, E., Flieder, D. B., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000630 · Cited by 4,532
Benefits and Harms of CT Screening for Lung Cancer
Bach, P. B., Mirkin, J. N., Oliver, T. K., Azzoli, C. G., Berry, D. A., Brawley, O. W., Byers, T., Colditz, G. A., Gould, M. K., Jett, J. R., et al. (2012) · JAMA · doi:10.1001/jama.2012.5521 · Cited by 1,237
Oxygen sensing and molecular adaptation to hypoxia
Bunn, H. F., & Poyton, R. Ο. (1996) · Physiological Reviews · doi:10.1152/physrev.1996.76.3.839 · Cited by 1,185
AMIDE: A Free Software Tool for Multimodality Medical Image Analysis
Loening, A. M., & Gambhir, S. S. (2003) · Molecular Imaging · doi:10.1162/153535003322556877 · Cited by 967
Bailey, C. J., Gross, J. L., Pieters, A., Bastien, A., & List, J. F. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60407-2 · Cited by 873
Regulation of glut1 mRNA by Hypoxia-inducible Factor-1
Chen, C., Pore, N., Behrooz, A., Ismail‐Beigi, F., & Maity, A. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010144200 · Cited by 769
Research works printed but not linked: 1
- L. C. Horn L D. H. Johnson Neoplasms of the Lung in Harrison’s Principles of Internal Medicine D. Kasper A. Fauci S. Hauser D. Longo J. Jameson J. Loscalzo Eds. (McGraw-Hill ed. 19 2015); http://accessmedicine.mhmedical.com/content.aspx?bookid=1130&Sectionid=69857702.
Cited by
Sorted by citations
Metabolic reprogramming and cancer progression
Faubert, B., Solmonson, A., & DeBerardinis, R. J. (2020) · Science · doi:10.1126/science.aaw5473 · Cited by 2,740
Mitochondrial Metabolism as a Target for Cancer Therapy
Vasan, K., Werner, M., & Chandel, N. S. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.06.019 · Cited by 762
Li, J., Liu, H., Takagi, S., Nitta, K., Kitada, M., Srivastava, S. P., Takagaki, Y., Kanasaki, K., & Koya, D. (2020) · JCI Insight · doi:10.1172/jci.insight.129034 · Cited by 246
Glucose Transporters as a Target for Anticancer Therapy
Pliszka, M., & Szablewski, L. (2021) · Cancers · doi:10.3390/cancers13164184 · Cited by 214
Gongora, C. A., Drobni, Z. D., Silva, T. Q. A. C., Zafar, A., Gong, J., Zlotoff, D. A., Gilman, H. K., Hartmann, S. E., Sama, S., Nikolaidou, S., et al. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.03.006 · Cited by 161
Metadata
- Authors
- Scafoglio, C. R., Villegas, B., Abdelhady, G., Bailey, S. T., Liu, J., Shirali, A. S., Wallace, W. D., Magyar, C. E., Grogan, T. R., Elashoff, D., Walser, T., Yanagawa, J., Aberle, D. R., Barrio, J. R., Dubinett, S. M., & Shackelford, D. B.
- Affiliations
- University of California, Los Angeles (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Scafoglio, Claudio R.
- Shackelford, David B.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2018-11-14
- Volume
- 10
- Issue
- 467
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC6428683
- OpenAlex
- W2901781577
- Cited by
- 176
- References
- 55
- Citations by year
- 2026: 22 · 2025: 21 · 2024: 35 · 2023: 17 · 2022: 22 · 2021: 29 · 2020: 15 · 2019: 14 · 2018: 1
- FWCI
- 4.46
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- American Cancer Society (130696-RSG-17-003-01-CCE)
- Tobacco-Related Disease Research Program (26IR-0009)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- SGLT2, lung adenocarcinoma, early-stage lung cancer, SGLT2 inhibitors, tumor growth inhibition, patient-derived xenografts, autochthonous mouse model, diagnostic imaging, therapeutic target
- MeSH terms
- Adenocarcinoma of Lung, Sodium-Glucose Transporter 2 Inhibitors, Aged, Aged, 80 and over, Animals, Biological Transport, Cell Differentiation, Female, Glucose, Humans, Male, Mice, Transgenic, Middle Aged, Neoplasm Staging, Precancerous Conditions, Survival Analysis, Mice, SCID, Xenograft Model Antitumor Assays, Cell Proliferation, Positron-Emission Tomography, Glucose Transporter Type 1, Sodium-Glucose Transporter 2, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
